Related Experiment Video
Updated: Sep 10, 2025

Perturbations of Circulating miRNAs in Irritable Bowel Syndrome Detected Using a Multiplexed High-throughput Gene Expression Platform
Published on: November 30, 2016
Implications of Shame for Patient-Reported Outcomes in Bowel Disorders of Gut-Brain Interaction
Inês A Trindade1, Amanda Blomsten2, Sanna Nybacka2
1Department of Molecular and Clinical Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden; EMBRACE Lab, Center for Health and Medical Psychology, Örebro University, Örebro, Sweden.
Background & Aims:
Bowel disorders of gut-brain interaction (DGBIs) are a highly stigmatized group of disorders. Although the link between stigma and shame is acknowledged overall, few studies focusing on health-related stigma mention shame, and research on shame in bowel DGBIs is nonexistent. The aim of this study was to examine the implications of shame in bowel DGBIs.
Methods:
Two Swedish population-based samples were included: a bowel DGBIs sample (n = 537) and a matched comparative sample without bowel symptoms (n = 1881). Participants completed an online survey with validated self-report scales. A cross-sectional mediation analysis via structural equation modeling and a moderation analysis were conducted to analyze the role of shame in the associations between bowel symptom severity and psychosocial outcomes.
Results:
The bowel DGBIs sample reported significantly higher levels of shame than the comparative sample. The mediation model, conducted with the bowel DGBIs sample, showed that shame was a mediator of the associations of bowel symptoms with general anxiety, depressive symptoms, quality of life, and activity impairment. Gastrointestinal-specific anxiety was not associated with any outcome of this model. Moderation results showed that shame was an exacerbator of the associations of bowel symptoms with higher severity of gastrointestinal-specific anxiety and depressive symptoms, and poorer quality of life.
Conclusions:
Shame appears to be a particularly important emotion deriving from the experience of gastrointestinal symptoms in bowel DGBIs and influencing the associations between these symptoms and important patient-reported outcomes. An empathetic physician-patient relationship and psychological therapies may be helpful for individuals with bowel DGBIs experiencing high levels of shame.
Related Concept Videos
Irritable Bowel Syndrome I: Introduction
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
Drugs for Treatment of Diarrhea-Predominant IBS
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Chronic Bowel Disorders: Introduction
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
Assessment of the Gastrointestinal System I: Subjective Data
Health History
The initial step in assessing the GI system is obtaining a comprehensive health history. This includes inquiring about the patient's history or presence of problems...
Assessment of the Gastrointestinal System II: Health Perception Pattern
Health Perception Patterns
Health perception patterns offer valuable insights into a patient's lifestyle habits and how they may impact their GI health. These patterns include:

